Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Handheld AI Device for Point-of-Care Skin Lesion Assessment Receives CE Mark

By HospiMedica International staff writers
Posted on 11 Jun 2026

DermaSensor (Miami, FL, USA) has received a Class IIb CE Mark for its handheld DermaSensor device, marking the start of the company’s global expansion strategy. More...

The certification demonstrates conformity with European Union safety, health, and environmental standards and enables commercialization across the European Economic Area. The company is now engaging with commercial partners and healthcare systems in Europe.

The device uses spectroscopy and artificial intelligence to evaluate suspicious skin lesions at the point of care and provide immediate results. CE-marked for use by qualified healthcare professionals, it helps inform whether lesions merit additional clinical care, such as dermatology referral or biopsy. The tool is intended for real-time assessment in both primary care and dermatology settings.

Beyond the European clearance, the device is Food and Drug Administration (FDA) cleared through the De Novo pathway and is currently available for sale in the United States. The CE Mark positions the company to pursue commercial opportunities with healthcare systems, physician networks, and distribution partners across Europe and in other markets that recognize CE standards. Skin cancer’s global prevalence continues to drive demand for technology-enabled early detection.

Performance and benefits have been reported across nine published studies involving more than 40 clinical sites and hundreds of clinicians. The company also announced a feasibility study with the United Kingdom’s National Health Service (NHS) to evaluate the impact of AI-assisted assessment when used by general practitioners. In addition, a strategic partnership with a large European distributor will support commercialization and accelerate market access in several major European markets, following a $5 million investment in the company’s recent Series B financing.

The organization is seeking additional partners and healthcare systems as it expands in Europe. In the United States, hundreds of healthcare provider institutions are using the device with thousands of patients each month, according to the announcement. Recent recognition includes placement on TIME’s 2024 Best Inventions list and Inc. Magazine’s 2025 Best in Innovation list.

“This is a transformative milestone for DermaSensor and an important step in our mission to improve access to skin cancer detection globally. We are the first and only automated device authorized by the FDA for detection of all three common skin cancers as well as the first and only automated skin cancer tool that can be used by physicians who are not already experts in dermatology,” said Cody Simmons, Co-Founder and CEO of DermaSensor.

“While many companies have tried, no such tools that are currently available in Europe have been able to achieve approval in the US, given the FDA’s high bar for clinical evidence. We are excited to now have the regulatory authorization to make our industry-leading product available to European Healthcare Providers (HCP’s) and their patients,” added Simmons.

Related Links
DermaSensor


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Tourniquet System
heidi– mein Tourniquet
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image Credit: Shutterstock

Explainable AI Examines Sepsis Mortality Risk and Emergency Care Delays

Preventing sepsis-related deaths in emergency departments (EDs) remains challenging because patient deterioration can result from multiple rapidly evolving and interconnected factors. These include triage... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image: A new automated approach could help predict which patients with dystonia will benefit from deep brain stimulation before surgery (Image Credit: Adobe Stock)

AI Uses Routine MRI to Predict Deep Brain Stimulation Response in Dystonia

Dystonia is a debilitating neurological movement disorder characterized by involuntary muscle contractions that cause abnormal movements and postures. Deep brain stimulation (DBS) is one of the few treatments... Read more

Health IT

view channel
Image Credit: Shutterstock

Telemonitoring Program Improves Quality of Life After Heart Failure Discharge

Heart failure is a chronic condition associated with high mortality, frequent hospitalizations, and reduced quality of life. Patients face particularly high risks of readmission and death after discharge,... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.